Andere Sprachen Nxera Pharma Co., Ltd. OTC Markets

Aktien

A0B7EK

JP3431300007

SOLT.F

Markt geschlossen - OTC Markets Andere Börsenplätze 18:20:04 20.06.2024			% 5 Tage	% 1. Jan.
9,43 ^USD	-5,70 %		-.--%	-5,70 %

27.06.	Nxera Pharma Co erreicht wichtigen F&E-Meilenstein in Zusammenarbeit mit AbbVie und sichert sich 10 Millionen Dollar Zahlung	MT
27.06.	Nxera Pharma Co., Ltd. erhält 10 Millionen USD von AbbVie, nachdem die Zusammenarbeit bei neurologischen Erkrankungen den ersten F&E-Meilenstein erreicht hat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	27.06.
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27.06.
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	27.06.
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023	18.06.
Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	31.05.
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30.05.
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30.05.
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30.05.
Nxera Pharma Co., Ltd. and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30.05.
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	10.05.
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	09.05.
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024	09.05.
Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18.04.
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	17.04.
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17.04.
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16.04.
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16.04.
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16.04.
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	15.04.
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	15.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nxera Pharma Co., Ltd. OTC Markets

Aktien

A0B7EK

JP3431300007

SOLT.F

Andere Sprachen

Filter